The following video is from Friday's Motley Fool Money roundtable discussion with host Chris Hill, and analysts Ron Gross, Jason Moser, and Charly Travers.
Some big tech companies were rocked this week by a new report from the research firm IDC. According to IDC, worldwide laptop and desktop shipments fell 14% in the first quarter. It's the sharpest decrease since IDC began tracking the data nearly 20 years ago. Shares of Microsoft (NASDAQ: MSFT ) , Hewlett-Packard (NYSE: HPQ ) , and Dell (NASDAQ: DELL ) all dropped on the news. In this installment of Motley Fool Money, our analysts talk about the slowdown of the PC, and the implications for investors.
It's been a frustrating path for Microsoft investors, who've watched the company fail to capitalize on the incredible growth in mobile over the past decade. However, with the release of its own tablet, along with the widely anticipated Windows 8 operating system, the company is looking to make a splash in this booming market. In this brand-new premium report on Microsoft, our analyst explains that, while the opportunity is huge, the challenges are many. He's also providing regular updates as key events occur, so make sure to claim a copy of this report now by clicking here.
10 Best International Stocks To Invest In Right Now: Donaldson Company Inc (DCI)
Donaldson Company, Inc. (Donaldson) is a worldwide manufacturer of filtration systems and replacement parts. The Company's product mix includes air and liquid filtration systems and exhaust and emission control products. The Company operates in two segments: Engine Products and Industrial Products. Products in the Engine Products segment consist of air filtration systems, exhaust and emissions systems, liquid filtration systems, and replacement filters. Products in the Industrial Products segment consist of dust, fume, and mist collectors, compressed air purification systems, air filtration systems for gas turbines, polytetrafluoroethylene (PTFE) membrane-based products, and specialized air filtration systems for applications including computer hard disk drives. Effective January 14, 2014, Donaldson Co Inc acquired bankrupt Entreprise Dubourg Pere et Fils Sarl.
Donaldson�� products are manufactured at 40 plants around the world and through three joint ventures. The Engine Products segment sells to original equipment manufacturers (OEMs) in the construction, mining, agriculture, aerospace, defense, and truck markets and to OEM dealer networks, independent distributors, private label accounts, and large equipment fleets. The Industrial Products segment sells to various industrial end-users, OEMs of gas-fired turbines and OEMs and end-users requiring clean air.
Advisors' Opinion:- [By Rich Duprey]
Filtration systems specialist Donaldson� (NYSE: DCI ) �announced yesterday�its second-quarter dividend of $0.13 per share, a�30% increase from the $0.10 per share payout it made last quarter.
- [By Rick Munarriz]
Friday
The market is typically quiet on Friday, but that's certainly not the case during earnings season. Donaldson (NYSE: DCI ) checks in with its latest quarterly results on Friday morning. - [By Marc Bastow]
Filtration parts and systems manufacturer Donaldson (DCI) raised its quarterly dividend 8% to 14 cents per share, payable on Dec. 20th to shareholders of record as of Dec. 9.
DCI Dividend Yield: 1.33% - [By James Miller Phd]
As we can see, the firm has a higher ROE than it peers: Sharps Compliance, Casella Waste Systems, Inc. (CWST), Donaldson Company, Inc. (DCI) and GSE Holding Inc. (GSEH).
Top 5 High Tech Companies To Buy For 2015: Sarepta Therapeutics Inc (SRPT)
Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., incorporated on July 22, 1980, biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company�� product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. The Company is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. The Company's program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). The Company initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.
The Company is also leveraging the capabilities of its RNA-based technology platforms to develop therapeutics for the treatment of infectious diseases. The Company's RNA-based drug programs are clinically evaluated for the treatment of DMD and have also demonstrated anti-viral activity in infectious diseases such as Ebola, Marburg and H1N1 influenza in certain animal models. The Company's lead product candidates are at various stages of development.
Duchenne Muscular Dystrophy Program
The Company's lead program is designed to address specific gene mutations that result in DMD by forcing the genetic machinery to skip over an adjacent contiguous piece of RNA and, thus, restore the ability of the cell to express a new, truncated but functional, dystrophin protein.
Eteplirsen is an antisense PMO-based therapeutic in clinical development for the treatment of individuals with DMD who have an error in the gene codi! ng for dystrophin that can be treated by skipping exon 51. Eteplirsen targets the frequent series of mutations that cause DMD. Eteplirsen has been granted orphan drug designation in the United States and European Union. In addition to the Company's lead product candidate, eteplirsen, the Company is actively pursues development of a product candidate that skips exon 45 through an IND-enabling collaboration.
Anti-Viral Programs
The Company is implementing its RNA-based technology platforms in its anti-viral programs for the development of therapeutics to treat viruses, such as Ebola, Marburg and influenza. The Company's arrangement with DoD supporting the development of the Company's Ebola and Marburg virus drug candidates provides funding for all clinical and licensure activities necessary to obtain approval of a New Drug Application (NDA), by the United States Food and Drug Administration (FDA), if DoD exercises all of its options under the arrangement. During the year ended December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and is exploring funding opportunities or partnerships with DHHS and industry collaborators to advance its development.
The Company's anti-viral therapeutic programs use the Company's translation suppression technology and applies its PMOplus chemistry backbone, an advanced generation of its base PMO chemistry backbone that selectively introduces positive backbone charges to improve selective interaction between the drug and its target. The Company's translation suppressing technology is based on Translation Suppressing Oligomers (TSOs), which are PMO-based compounds that stop or suppress the translation of a specific protein by binding to their specific target sequence in mRNA.
The Company is pursuing development and regulatory approval of its Ebola and Marburg hemorrhagic fever virus product candidates under the FDA's Animal Rule. The Company's lead product candidate against the Ebola virus infec! tion is A! VI-6002. For Marburg virus infection, the Company's lead product candidate has been AVI-6003. In February 2012, the Company announced that the Company received approval from the FDA to remove one of the two oligomers composing AVI-6003 and proceed with a single oligomer approach, AVI-7288, given that efficacy in non-human primates has been demonstrated to be attributable to this single oligomer. The Company is exploring the feasibility of alternate routes of administration of its Ebola and Marburg drug candidates, and at DoD's invitation, the Company is developing a proposal to be submitted for a study to demonstrates feasibility of the intramuscular route.
AVI-6002, which is a combination of AVI-7537 and AVI-7539, is designed for post-exposure prophylaxis after documented or suspected exposure to the Ebola virus. The Company is evaluating the feasibility of developing AVI-7537 as a single agent for the post-exposure prophylaxis after documented or suspected exposure to Ebola virus. AVI-6003, which is a combination of AVI-7287 and AVI-7288, is designed for post-exposure prophylaxis after documented or suspected exposure to Marburg virus. In February 2012, the Company announced that the Company received approval from the FDA to proceed with AVI-7288 as a single agent against Marburg virus infection. The Company intends to proceed with dosing AVI-7288 in the Phase I multiple ascending dose studies and in non-human primate studies.
Influenza Program
The Company's anti-viral therapeutic programs are also focused on the development of the Company's product candidates designed to treat pandemic influenza viruses. AVI-7100 is the Company's lead product candidate for the treatment of influenza and employs its PMOplus technology. In June 2011, the Company initiated dosing of AVI-7100 through intravenous infusion in single-ascending doses in up to 48 healthy adult volunteers. As of December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and are exp! loring fu! nding opportunities or partnerships to advance its development.
The Company has developed three new phosphorodiamidate-linked morpholino oligomers (PMO)-based chemistry platforms in addition to its original PMO-based technology. The Company's PMO-based molecules are designed to sterically block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this selective targeting, two distinct biologic mechanisms of action can be initiated: modulation of pre-mRNA splicing and inhibition of mRNA translation.
The Company competes with GlaxoSmithKline plc, Toyama Chemical, Alnylam Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corp., Isis Pharmaceuticals, Inc., Prosensa, and Santaris Pharma A/S.
Advisors' Opinion:- [By Selena Maranjian]
The biggest new holdings are Liberty Media�and the iShares MSCI Mexico Capped Investable Market Index Fund ETF. Other new holdings of interest include Sarepta Therapeutics (NASDAQ: SRPT ) . Sarepta stock has soared about ninefold over the past year, and some still see it as undervalued. After Sarepta petitioned the FDA for accelerated approval for its Duchenne muscular dystrophy drug, eteplirsen, the FDA requested more information. That sent shares lower, but management is optimistic about its recent interactions with the FDA.
- [By Leo Sun]
Prosensa: GSK doesn't believe in it -- so why should you?
Throughout 2013, Prosensa and its former partner GlaxoSmithKline competed against Sarepta Therapeutics (NASDAQ: SRPT ) to launch the first dedicated treatment for Duchenne muscular dystrophy (DMD).
Top 5 High Tech Companies To Buy For 2015: Palo Alto Networks Inc (PANW)
Palo Alto Networks, Inc., incorporated in March 2005, offers a network security platform that allows enterprises, service providers, and government entities to secure their networks. The core of its platform is the Company�� firewall that delivers natively integrated application, user, and content visibility and control through its operating system, hardware, and software architecture. The Company primarily sells its products and services to end-customers through distributors, resellers, and partners, and directly to end-customers (collectively partners), who are supported by its sales and marketing organization, in the Americas, in Europe, the Middle East, and Africa (EMEA), and in Asia Pacific and Japan (APAC). Its products and services can address a range of its end-customers��network security requirements, from the data center to the network perimeter, as well as the distributed enterprise, which includes branch offices and a number of mobile devices. It introduced PA-5000 Series and GlobalProtect subscription service in March 2011 and the PA-200 and WildFire subscription service in November 2011.
The Company�� platform is delivered in an appliance form factor and includes a suite of subscription services, as well as support and maintenance. Its subscription services can be activated on any of its appliances. All of the Company�� appliances incorporate its PAN-OS operating system and are based on its identification technologies, App-ID, User-ID, and Content-ID, which allow security policies to be defined within the context of applications, users, and content. It delivers these capabilities through a single-pass parallel processing architecture that simultaneously performs multiple identification, security and networking functions. The Company serves the enterprise network security market, which consists of Firewall/ Virtual Private Network (VPN), Unified Threat Management (UTM), Web Gateway, Intrusion Detection and Prevention (IDP/IPS), and VPN technologies. The Company deriv! ed 62% of its total revenue from the Americas, 27% from Europe, the Middle East, and Africa (EMEA), and 11% from Asia Pacific and Japan (APAC) as of January 31, 2012.
The Company derives revenue from sales of its products and services, which together comprise its platform. Product revenue is primarily generated from sales of its Firewall. The Company�� Threat Prevention, universal resource locator (URL) Filtering, and GlobalProtect subscriptions provide its end-customers with real-time access to the antivirus, intrusion prevention, Web filtering, and malware protection capabilities across fixed and mobile devices. The Company�� application classification engine, called App-ID, uses multiple identification techniques to determine the exact identity of applications traversing the network. App-ID is the foundational classification engine that provides the core traffic classification to all other functions in its platform. The App-ID classification is used to invoke other security functions.
App-ID uses a series of classification techniques to identify an application. App-ID classifies all network traffic, including business applications, consumer applications, and network protocols, across all ports. User-ID integrates its platform with a range of enterprise user directories and technologies, including Active Directory, eDirectory, Open LDAP, Citrix Terminal Server, Microsoft Exchange, Microsoft Terminal Server, and ZENworks. Content-ID is a collection of technologies that enables its subscription services. Content-ID combines a real-time threat prevention engine, cloud-based analysis service, and a URL categorization database to limit unauthorized data and file transfers, detect and block a range of threats, and control non-work related Web surfing. Its WildFire, cloud-based analysis service provides a real-time analysis engine for detecting previously unseen malware. Its URL filtering database consists of millions of URLs across many categories and is designed to monitor a! nd contro! l employee Web surfing activities. Single-Pass Parallel Processing Architecture (SP3) has two elements: single-pass software and parallel processing hardware.
The PAN-OS Operating System operating system provides the foundation for its network security platform and contains App-ID, User-ID, and Content-ID. PAN-OS performs the core functions of its platform, while also providing the networking, security, and management functions needed for implementation. The PAN-OS networking functions include dynamic routing, switching, high availability, and VPN support, which enables deployment into a range of networking environments. PAN-OS also includes attack protection capabilities, such as blocking invalid or malformed packets, IP defragmentation, TCP reassembly, and network traffic normalization. The Company also offers, such as application traffic management, solution design and planning, configuration, and firewall migration. Its education services provide classroom-style training and are primarily delivered through its partners.
The Company competes with Cisco, Juniper, Intel, IBM, HP, Check Point Software, Fortinet and Sourcefire.
Advisors' Opinion:- [By Jake L'Ecuyer]
Palo Alto Networks (NYSE: PANW) was also up, gaining 6.89 percent to $49.26 after the company reported better-than-expected fiscal first-quarter results.
Top 5 High Tech Companies To Buy For 2015: InSite Vision Inc (INSV)
InSite Vision Incorporated (InSite), incorporated in 1986, is an ophthalmic product development company advancing ophthalmic pharmaceutical products to address unmet eye care needs. The Company's current portfolio of products is based on the Company's DuraSite sustained drug delivery technology. Its DuraSite sustained drug delivery technology is a synthetic polymer-based formulation designed to extend the residence time of a drug relative to conventional topical therapies. It enables topical delivery of a drug as a solution, gel or suspension and can be customized for delivering a wide variety of drug candidates. The Company is focused its research and development and commercial support efforts on the topical products formulated with its DuraSite drug delivery technology. It may also utilize its DuraSite technology platform for the formulation of new ocular product candidates using either non drugs or compounds developed by others for non-ophthalmic indications.
AzaSite (azithromycin ophthalmic solution) 1% is a DuraSite formulation of azithromycin developed as a spectrum ocular antibiotic and approved by the United States Food and Drug Administration (FDA) to treat bacterial conjunctivitis (pink eye). Azithromycin has a spectrum of antibiotic activity and is used to treat respiratory and other infections in its oral and parenteral forms.
Besivance (besifloxacin ophthalmic suspension) 0.6% is a DuraSite formulation of besifloxacin, a spectrum ocular antibiotic approved by the FDA to treat bacterial conjunctivitis (pink eye). Besivance is the fluoroquinolone specifically developed for ophthalmic use. AzaSite Plus (ISV-502) is a fixed combination of azithromycin and dexamethasone in DuraSite for the treatment of ocular inflammation and infection (blepharitis and/or blepharoconjunctivitis).
DexaSite (ISV-305) is a DuraSite formulation of dexamethasone in development for the treatment of ocular inflammation. DexaSite is included in the Phase 3 clinical trial SPA for ! AzaSite Plus. The Company developed a topical formulation of the corticosteroid dexamethasone to treat eye inflammation caused by infections, injury, surgery or other conditions.
BromSite (ISV-303) is a DuraSite formulation of bromfenac in development for the treatment of post-operative inflammation and eye pain. ISV-101 is a DuraSite formulation with a low concentration of bromfenac for the treatment of dry eye disease.
The Company competes with Alcon Laboratories, Inc., Allergan, Inc., Bausch & Lomb, Novartis Ophthalmics, Johnson & Johnson, Merck & Co. and Pfizer.
Advisors' Opinion:- [By CRWE]
Today, INSV surged (+2.77%) up +0.009 at $.334 with 24,100 shares in play thus far (ref. google finance Delayed: 11:27AM EDT July 8, 2013).
InSite Vision Incorporated previously reported it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) on its DuraSite庐 2 next-generation enhanced drug delivery system. DuraSite 2 provides a broad platform for developing topically delivered ocular drugs with enhanced tissue penetration in order to improve efficacy and dosing convenience. The patent is expected to provide protection to 2029 for both the delivery system and the drugs that are formulated with DuraSite 2.
No comments:
Post a Comment